Streetbeat News

Regulatory

EH

EHang Holdings Limited (NASDAQ:EH) announced a suggested retail price of $410,000 for its EH216-S pilotless eVTOL aircraft for global markets outside China, effective from April 1, 2024. The EH216-S features autonomous flight, electric propulsion, safety features, and intelligent systems for cluster management, aiming at various urban air mobility applications. It also secured the world's first Type Certificate and Standard Airworthiness Certificate for pilotless passenger-carrying eVTOL aircraft from the CAAC in 2023, highlighting EHang's commitment to safety and quality. This pricing strategy is intended to meet international demand and promote the adoption of innovative urban air mobility solutions.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 2:14 pm

ACHR

Archer is advancing in its FAA certification process by constructing three piloted Midnight aircraft that conform to the intended type design. The manufacturing of key components is in progress, with final assembly to start soon in San Jose, California. These aircraft will be utilized in FAA 'for credit' testing, marking a significant step towards Archer's commercialization goal in 2025.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 2:04 pm

AAPL

CRM

F

MSTR

NVDA

TSLA

Bitcoin, Ethereum, and Dogecoin prices rise after MicroStrategy acquires $37M in BTC. Janet Yellen calls for new crypto regulations, emphasizing stablecoins. Ark Invest's Cathie Wood predicts Bitcoin will attract investors from gold. Solana experiences a 5-hour outage. US markets see mixed movements with Snap and others declining, while the Fear & Greed Index indicates greed. Tesla, Ford, and NIO make headlines in the EV sector. Tech updates include Nvidia's focus on AI and Apple's iPhone 16 camera redesign. Salesforce threatens to withhold bonuses over training goals.

Portfolio Pulse from Akanksha Bakshi

February 07, 2024 | 1:52 pm

CETY

Clean Energy Technologies, Inc. (CETY) announced its affiliate, Vermont Renewable Gas, LLC, received a favorable order from the Maine Public Utilities Commission, granting New Renewable Resource Certification for a 2.2 MW biogas generator facility. This certification allows the facility to participate in Maine's Renewable Portfolio Standard program, projecting $5.2M in revenue over 10 years. CETY will design, build, and operate the $10M facility, expected to generate over 18,000 MWh of renewable electricity and 1,500 tons of BioChar annually. The project benefits from the Inflation Reduction Act and aligns with CETY's mission to expand its clean energy solutions.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:36 pm

EVAX

Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage TechBio company, has regained compliance with Nasdaq's minimum bid price requirement. The company's shares maintained a closing bid price of $1.00 or greater for ten consecutive business days, from January 22, 2024, to February 02, 2024, according to a Notification Letter from Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:34 pm

TRIB

Trinity Biotech has applied for a PLA (Proprietary Laboratory Analyses) code for its early Sjogren's Syndrome test panel, indicating a move to enhance its diagnostic offerings.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:34 pm

EQIX

Equinix, Inc. (NASDAQ:EQIX) has executed a new Power Purchase Agreement (PPA) in Australia with TagEnergy for 151 megawatts of renewable energy from the Golden Plains Wind Farm – East project, expected to be online by 2029. This marks Equinix's first long-term renewable energy agreement in the Asia-Pacific region, contributing to its goal of 100% renewable energy coverage across its operations globally. Equinix has executed 21 PPAs globally, resulting in 3,000,000 MWh of renewable energy, and aims to become climate neutral by 2030.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:27 pm

RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced the Italian Medicine Agency (AIFA) approved reimbursement for IMCIVREE (setmelanotide) for treating obesity and controlling hunger in Bardet-Biedl syndrome (BBS) patients in Italy. This marks the first and only treatment option authorized in the European Union for this rare neuroendocrine disease, with Rhythm aiming to expand access across Europe. BBS is characterized by severe obesity and hyperphagia, among other symptoms, with an estimated 200 patients identified in Italy.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:25 pm

MAIA

MAIA Biotechnology's recent publication highlights the effectiveness of THIO in treating small cell lung cancer (SCLC). THIO not only activates anti-tumor responses but also depletes cancer initiating cells (CICs), reducing tumor initiation and metastasis. The FDA has previously awarded THIO orphan drug designation for SCLC treatment.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:23 pm

DUOT

Duos Technologies Group, Inc. (NASDAQ:DUOT) has been awarded a patent for its AI technology aimed at detecting defects in trains, enhancing rail safety and operational efficiency. The patent covers technology integrating Machine Learning and a 'human in the loop' feature for improved inspections. This innovation is expected to prevent derailments and set new safety standards in the rail industry. Duos has also secured a multi-year contract with a Class 1 railroad, leveraging this AI technology.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 1:22 pm